Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Low-frequency HIV-1 drug resistance mutations can be clinically significant but must be interpreted with caution.

Johnson JA, Geretti AM.

J Antimicrob Chemother. 2010 Jul;65(7):1322-6. doi: 10.1093/jac/dkq139. Review.

PMID:
20466851
2.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
3.

Impact of genotypic resistance testing on selection of salvage regimen in clinical practice.

Haupts S, Ledergerber B, Böni J, Schüpbach J, Kronenberg A, Opravil M, Flepp M, Speck RF, Grube C, Rentsch K, Weber R, Günthard HF; Swiss HIV Cohort Study..

Antivir Ther. 2003 Oct;8(5):443-54.

PMID:
14640392
4.

Genotypic resistance tests for the clinical management of patients with primary HIV infection.

Narciso P, Lazzarin A.

Scand J Infect Dis Suppl. 2003;106:66-70. Review.

PMID:
15000588
5.

Genotypic resistance tests for the management of structured therapeutic interruptions after multiple drug failure.

Montroni M, Monforte AD.

Scand J Infect Dis Suppl. 2003;106:79-81. Review.

PMID:
15000591
6.

Genotypic resistance tests for the management of the HIV-infected patient with non-B viral isolates.

Visco-Comandini U, Balotta C.

Scand J Infect Dis Suppl. 2003;106:75-8. Review.

PMID:
15000590
7.

Antiretroviral resistance testing for clinical management.

Youree BE, D'Aquila RT.

AIDS Rev. 2002 Jan-Mar;4(1):3-12. Review.

PMID:
11998782
8.

Detection and significance of minority quasispecies of drug-resistant HIV-1.

Metzner KJ.

J HIV Ther. 2006 Dec;11(4):74-81. Review. No abstract available.

PMID:
17578210
9.

Updated European recommendations for the clinical use of HIV drug resistance testing.

Vandamme AM, Sönnerborg A, Ait-Khaled M, Albert J, Asjo B, Bacheler L, Banhegyi D, Boucher C, Brun-Vézinet F, Camacho R, Clevenbergh P, Clumeck N, Dedes N, De Luca A, Doerr HW, Faudon JL, Gatti G, Gerstoft J, Hall WW, Hatzakis A, Hellmann N, Horban A, Lundgren JD, Kempf D, Miller M, Miller V, Myers TW, Nielsen C, Opravil M, Palmisano L, Perno CF, Phillips A, Pillay D, Pumarola T, Ruiz L, Salminen M, Schapiro J, Schmidt B, Schmit JC, Schuurman R, Shulse E, Soriano V, Staszewski S, Vella S, Youle M, Ziermann R, Perrin L.

Antivir Ther. 2004 Dec;9(6):829-48.

PMID:
15651743
10.

Persistence of HIV-1 drug resistance mutations and emergence during antiretroviral treatment interruption: considerations from a clinical case.

Torti C, Moretti F, Uccelli MC, Tirelli V, Quiros-Roldan E, Gargiulo F, Carosi G.

Med Sci Monit. 2003 Apr;9(4):CS16-9.

PMID:
12709675
11.

Successful application of laboratory tools for the detection of HIV drug resistance in routine clinical care in Georgia.

Chkhartishvili N, Dvali N, Gochitashvili N, Sharvadze L, Tsertsvadze T.

Georgian Med News. 2008 Dec;(165):16-22.

PMID:
19124911
12.

Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes.

Simen BB, Simons JF, Hullsiek KH, Novak RM, Macarthur RD, Baxter JD, Huang C, Lubeski C, Turenchalk GS, Braverman MS, Desany B, Rothberg JM, Egholm M, Kozal MJ; Terry Beirn Community Programs for Clinical Research on AIDS..

J Infect Dis. 2009 Mar 1;199(5):693-701. doi: 10.1086/596736.

PMID:
19210162
13.

Genotypic resistance tests in the management of the HIV-infected patient at virological failure.

Aceti A, Carosi G.

Scand J Infect Dis Suppl. 2003;106:61-6. Review.

PMID:
15000587
14.

Simple PCR assays improve the sensitivity of HIV-1 subtype B drug resistance testing and allow linking of resistance mutations.

Johnson JA, Li JF, Wei X, Lipscomb J, Bennett D, Brant A, Cong ME, Spira T, Shafer RW, Heneine W.

PLoS One. 2007 Jul 25;2(7):e638.

15.

Human immunodeficiency virus type 1 (HIV-1) genotyping in Rio de Janeiro, Brazil: assessing subtype and drug-resistance associated mutations in HIV-1 infected individuals failing highly active antiretroviral therapy.

Couto-Fernandez JC, Silva-de-Jesus C, Veloso VG, Rachid M, Gracie RS, Chequer-Fernandez SL, Oliveira SM, Arakaki-Sanchez D, Chequer PJ, Morgado MG.

Mem Inst Oswaldo Cruz. 2005 Feb;100(1):73-8.

16.

Net benefits of resistance testing directed therapy compared with standard of care in HIV-infected patients with virological failure: A meta-analysis.

Ena J, Ruiz de Apodaca RF, Amador C, Benito C, Pasquau F.

Enferm Infecc Microbiol Clin. 2006 Apr;24(4):232-7.

PMID:
16725082
17.

Antiretroviral drug resistance and resistance testing.

Gallant JE.

Top HIV Med. 2005 Dec-2006 Jan;13(5):138-42. Review.

18.

Antiretroviral drug resistance testing.

Sen S, Tripathy SP, Paranjape RS.

J Postgrad Med. 2006 Jul-Sep;52(3):187-93. Review.

19.

Genotypic resistance tests for the management of the HIV-infected pregnant woman.

Bassetti D, Cargnel A.

Scand J Infect Dis Suppl. 2003;106:70-4. Review.

PMID:
15000589
20.

Algorithms for the interpretation of HIV-1 genotypic drug resistance information.

Vercauteren J, Vandamme AM.

Antiviral Res. 2006 Sep;71(2-3):335-42. Review.

PMID:
16782210
Items per page

Supplemental Content

Support Center